ライフサイエンスコーパス: temporal artery biopsy

1 y ) was performed (diagnostic standard [ TAB temporal artery biopsy ]).

2 nts suspected of having GCA should undergo a temporal artery biopsy.

3 Vascular tissue was obtained at the time of temporal artery biopsy.

4 pares the use of invasive procedures such as temporal artery biopsy.

5 erpes zoster antigen was detected on several temporal artery biopsies.

6 l in predicting the likelihood of a positive temporal artery biopsy among patients with a clinical su

7 tion of biochemical markers of inflammation, temporal artery biopsy and positron emission tomography/

8 genesis of the disease but have not replaced temporal artery biopsy as the gold standard for securing

9 A temporal artery biopsy confirmed the diagnosis of giant

10 od (each p < .001); that of enucleations and temporal artery biopsies decreased significantly 38- and

11 However, a temporal artery biopsy excluded GCA, showing segmental s

12 Temporal artery biopsy findings were negative in 42% of

13 ), and 28 patients had negative results of a temporal artery biopsy for GCA (group 2).

14 Results of a prior lumbar puncture and temporal artery biopsy from an outside hospital were neg

15 1 core studies, 39% of patients referred for temporal artery biopsy had positive results.

16 In GCA, temporal artery biopsy may not be required in patients w

17 iopsy-positive GCA underwent two consecutive temporal artery biopsies, one prior to therapy and one w

18 cent of the control samples were obtained by temporal artery biopsy performed within 1 year of the bi

19 rd to age, frequency of positive findings on temporal artery biopsy (placebo 87%, MTX 79%), or comorb

20 In 56.5% of patients with TAB temporal artery biopsy -positive results (35 of 62), MR

21 Temporal artery biopsy practices vary greatly among trea

22 by angiography and 74 control patients with temporal artery biopsy-proven GCA without large vessel i

23 Temporal artery biopsy remains the diagnostic procedure

24 In GCA, temporal artery biopsy remains the standard for definiti

25 owed a significant association of VZV DNA to temporal artery biopsy samples positive for GCA compared

26 Controls had negative temporal artery biopsy specimens during the same 32-year

27 Temporal artery biopsy specimens from patients with GCA

28 The inflammatory response in temporal artery biopsy specimens was characterized by se

29 In a randomized masked study, 64 temporal artery biopsy specimens were analyzed by PCR fo

30 stochemical, and ultrastructural analyses of temporal artery biopsy specimens.

31 88.7% and specificity was 75.0% for the TAB temporal artery biopsy subcohort (first observer).

32 giant cell arteritis -negative results ( TAB temporal artery biopsy subcohort and total study cohort,

33 ic standard TAB temporal artery biopsy ( TAB temporal artery biopsy subcohort).

34 ers, with good interobserver agreement ( TAB temporal artery biopsy subcohort, kappa = 0.718; total s

35 In 53.0% of patients (98 of 185), temporal artery biopsy ( TAB temporal artery biopsy ) wa

36 comparison with the diagnostic standard TAB temporal artery biopsy ( TAB temporal artery biopsy subc

37 Patients who underwent temporal artery biopsy (TAB) from 01/01/1995 through 12/

38 The temporal artery biopsy (TAB) has long been the standard

39 Frozen section temporal artery biopsy (TAB) may prevent a contralateral

40 Temporal artery biopsy (TAB) remains the gold standard f

41 We prospectively examined temporal artery biopsy (TAB) tissue from 50 consecutive

42 Temporal artery biopsy (TAB), performed for the diagnosi

43 ella-zoster virus antigen) was detectable in temporal artery biopsies taken from individuals with gia

44 ts (98 of 185), temporal artery biopsy ( TAB temporal artery biopsy ) was performed (diagnostic stand

45 ted GCA was examined in peripheral blood and temporal artery biopsies with protein quantification ass

46 ents aged >=50 years with biopsy-proven GCA (temporal artery biopsy within 2 weeks of diagnosis and >